Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Guillain-Barré Syndrome
NCT04752566Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Guillain-Barré syndrome (GBS) comparing Eculizumab with Placebo (2 arms). Primary endpoint: Time to First Reaching a Hughes Functional Grade (FG) Score <=1. Started Mar 2021; status: completed.
02
Drugs
eculizumab
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT04752566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752566.